Drugs that contain Hydromorphone Hydrochloride
1. Dilaudid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6589960 | FRESENIUS KABI USA | Hydromorphone and hydrocodone compositions and methods for their synthesis |
Nov, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9731082 | FRESENIUS KABI USA | Drug container |
Apr, 2032
(7 years from now) | |
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(9 years from now) | |
Market Authorisation Date: 16 January, 2020
Treatment: NA
Dosage: INJECTABLE;INJECTION
DILAUDID family patents
2. Dilaudid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6589960 | RHODES PHARMS | Hydromorphone and hydrocodone compositions and methods for their synthesis |
Nov, 2020
(3 years ago) | |
Market Authorisation Date: 07 December, 1992
Treatment: NA
Dosage: SOLUTION;ORAL; TABLET;ORAL
DILAUDID family patents
3. Dilaudid-hp patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6589960 | FRESENIUS KABI USA | Hydromorphone and hydrocodone compositions and methods for their synthesis |
Nov, 2020
(3 years ago) | |
| US9731082 | FRESENIUS KABI USA | Drug container |
Apr, 2032
(7 years from now) | |
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(9 years from now) | |
Market Authorisation Date: 16 January, 2020
Treatment: NA
Dosage: INJECTABLE;INJECTION
DILAUDID-HP family patents
4. Exalgo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5914131 | SPECGX LLC | Hydromorphone therapy |
Jul, 2014
(9 years ago) | |
| US5702725 | SPECGX LLC | Hydromorphone therapy |
Jul, 2014
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Mar 01, 2013 |
Market Authorisation Date: 01 March, 2010
Treatment: Management of moderate to severe pain
Dosage: TABLET, EXTENDED RELEASE;ORAL
EXALGO family patents
5. Palladone patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958452 | PURDUE PHARMA LP | Extruded orally administrable opioid formulations |
Nov, 2014
(9 years ago) | |
| US6743442 | PURDUE PHARMA LP | Melt-extruded orally administrable opioid formulations |
Nov, 2014
(9 years ago) | |
| US5965161 | PURDUE PHARMA LP | Extruded multi-particulates |
Nov, 2014
(9 years ago) | |
| US6335033 | PURDUE PHARMA LP | Melt-extrusion multiparticulates |
Nov, 2014
(9 years ago) | |
| US6706281 | PURDUE PHARMA LP | Melt-extrusion multiparticulates |
Nov, 2014
(9 years ago) | |
| US6589960 | PURDUE PHARMA LP | Hydromorphone and hydrocodone compositions and methods for their synthesis |
Nov, 2020
(3 years ago) | |
Market Authorisation Date: 24 September, 2004
Treatment: Management of persistent, moderate to severe pain in patients requiring continuous, around-the-clock analgesia with a high potency opioid for an extended period of time generally weeks to months or lo...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
PALLADONE family patents